Align Technology Inc. (ALGN)

$220.45

-5.6

(-2.48%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $218.85
    $225.56
    $220.45
    downward going graph

    0.73%

    Downside

    Day's Volatility :2.97%

    Upside

    2.26%

    downward going graph
  • $176.34
    $413.20
    $220.45
    downward going graph

    20.01%

    Downside

    52 Weeks Volatility :57.32%

    Upside

    46.65%

    downward going graph

Returns

PeriodAlign Technology Inc.Sector (Health Care)S&P500
3 Months
-26.85%
6.5%
5.9%
6 Months
-14.47%
7.1%
10.4%
1 Year
-33.49%
9.8%
18.2%
3 Years
-64.43%
14.2%
22.1%

Highlights

Market Capitalization
18.4B
Book Value
$49.94
Earnings Per Share (EPS)
5.9
PE Ratio
41.49
PEG Ratio
1.96
Wall Street Target Price
316.75
Profit Margin
11.8%
Operating Margin TTM
15.45%
Return On Assets TTM
7.02%
Return On Equity TTM
12.77%
Revenue TTM
3.9B
Revenue Per Share TTM
51.54
Quarterly Revenue Growth YOY
5.800000000000001%
Gross Profit TTM
2.6B
EBITDA
816.8M
Diluted Eps TTM
5.9
Quarterly Earnings Growth YOY
0.22
EPS Estimate Current Year
9.56
EPS Estimate Next Year
10.76
EPS Estimate Current Quarter
1.97
EPS Estimate Next Quarter
2.38

Analyst Recommendation

Buy
    68%Buy
    22%Hold
    9%Sell
Based on 22 Wall street analysts offering stock ratings for Align Technology Inc.(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
5
5
4
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 43.68%

Current $220.45
Target $316.75

Company Financials

FY18Y/Y Change
Revenue
2.0B
↑ 33.47%
Net Income
400.2M
↑ 72.95%
Net Profit Margin
20.35%
↑ 4.64%
FY19Y/Y Change
Revenue
2.4B
↑ 22.39%
Net Income
442.8M
↑ 10.63%
Net Profit Margin
18.4%
↓ 1.95%
FY20Y/Y Change
Revenue
2.5B
↑ 2.71%
Net Income
1.8B
↑ 301.08%
Net Profit Margin
71.84%
↑ 53.44%
FY21Y/Y Change
Revenue
4.0B
↑ 59.9%
Net Income
772.0M
↓ 56.53%
Net Profit Margin
19.53%
↓ 52.31%
FY22Y/Y Change
Revenue
3.7B
↓ 5.51%
Net Income
361.6M
↓ 53.17%
Net Profit Margin
9.68%
↓ 9.85%
FY23Y/Y Change
Revenue
3.9B
↑ 3.42%
Net Income
445.1M
↑ 23.09%
Net Profit Margin
11.52%
↑ 1.84%
Q4 FY22Q/Q Change
Revenue
901.5M
↑ 1.25%
Net Income
41.8M
↓ 42.54%
Net Profit Margin
4.63%
↓ 3.54%
Q1 FY23Q/Q Change
Revenue
943.1M
↑ 4.62%
Net Income
87.8M
↑ 110.17%
Net Profit Margin
9.31%
↑ 4.68%
Q2 FY23Q/Q Change
Revenue
1.0B
↑ 6.26%
Net Income
111.8M
↑ 27.35%
Net Profit Margin
11.16%
↑ 1.85%
Q3 FY23Q/Q Change
Revenue
960.2M
↓ 4.19%
Net Income
121.4M
↑ 8.6%
Net Profit Margin
12.65%
↑ 1.49%
Q4 FY23Q/Q Change
Revenue
956.7M
↓ 0.36%
Net Income
124.0M
↑ 2.13%
Net Profit Margin
12.96%
↑ 0.31%
Q1 FY24Q/Q Change
Revenue
997.4M
↑ 4.25%
Net Income
105.0M
↓ 15.31%
Net Profit Margin
10.53%
↓ 2.43%
FY18Y/Y Change
Total Assets
2.1B
↑ 15.45%
Total Liabilities
799.6M
↑ 27.42%
FY19Y/Y Change
Total Assets
2.5B
↑ 21.84%
Total Liabilities
1.2B
↑ 44.39%
FY20Y/Y Change
Total Assets
4.8B
↑ 93.13%
Total Liabilities
1.6B
↑ 38.22%
FY21Y/Y Change
Total Assets
5.9B
↑ 23.03%
Total Liabilities
2.3B
↑ 45.34%
FY22Y/Y Change
Total Assets
5.9B
↑ 0.1%
Total Liabilities
2.3B
↑ 1.17%
FY23Y/Y Change
Total Assets
6.1B
↑ 2.29%
Total Liabilities
2.5B
↑ 4.55%
Q4 FY22Q/Q Change
Total Assets
5.9B
↑ 0.59%
Total Liabilities
2.3B
↑ 5.79%
Q1 FY23Q/Q Change
Total Assets
5.9B
↓ 0.78%
Total Liabilities
2.4B
↑ 3.19%
Q2 FY23Q/Q Change
Total Assets
6.1B
↑ 4.12%
Total Liabilities
2.5B
↑ 3.5%
Q3 FY23Q/Q Change
Total Assets
6.3B
↑ 2.83%
Total Liabilities
2.5B
↑ 0.42%
Q4 FY23Q/Q Change
Total Assets
6.1B
↓ 3.71%
Total Liabilities
2.5B
↓ 2.52%
Q1 FY24Q/Q Change
Total Assets
6.2B
↑ 1.18%
Total Liabilities
2.4B
↓ 2.34%
FY18Y/Y Change
Operating Cash Flow
554.7M
↑ 26.48%
Investing Cash Flow
6.9M
↓ 102.75%
Financing Cash Flow
-369.4M
↑ 172.65%
FY19Y/Y Change
Operating Cash Flow
747.3M
↑ 34.72%
Investing Cash Flow
-350.4M
↓ 5159.1%
Financing Cash Flow
-485.5M
↑ 31.43%
FY20Y/Y Change
Operating Cash Flow
662.2M
↓ 11.39%
Investing Cash Flow
-231.5M
↓ 33.94%
Financing Cash Flow
-30.8M
↓ 93.65%
FY21Y/Y Change
Operating Cash Flow
1.2B
↑ 77.07%
Investing Cash Flow
-563.4M
↑ 143.38%
Financing Cash Flow
-458.3M
↑ 1387.7%
FY22Y/Y Change
Operating Cash Flow
568.7M
↓ 51.5%
Investing Cash Flow
-213.3M
↓ 62.14%
Financing Cash Flow
-501.7M
↑ 9.46%
Q4 FY22Q/Q Change
Operating Cash Flow
144.7M
↓ 45.7%
Investing Cash Flow
-55.8M
↓ 34.67%
Financing Cash Flow
-200.2M
↓ 1936.92%
Q1 FY23Q/Q Change
Operating Cash Flow
199.9M
↑ 38.14%
Investing Cash Flow
-52.8M
↓ 5.34%
Financing Cash Flow
-259.0M
↑ 29.36%
Q2 FY23Q/Q Change
Operating Cash Flow
251.8M
↑ 25.95%
Investing Cash Flow
-125.5M
↑ 137.53%
Financing Cash Flow
-931.0K
↓ 99.64%
Q3 FY23Q/Q Change
Operating Cash Flow
287.2M
↑ 14.07%
Investing Cash Flow
-4.3M
↓ 96.57%
Financing Cash Flow
11.8M
↓ 1371.0%

Technicals Summary

Sell

Neutral

Buy

Align Technology Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Align Technology Inc.
Align Technology Inc.
-7.21%
-14.47%
-33.49%
-64.43%
13.68%
Stryker Corporation
Stryker Corporation
-3.84%
5.16%
12.86%
24.25%
52.69%
Boston Scientific Corp.
Boston Scientific Corp.
-3.68%
21.48%
41.72%
68.89%
76.47%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-34.8%
-18.49%
-34.85%
-45.17%
-15.86%
Abbott Laboratories
Abbott Laboratories
1.03%
-5.4%
-7.12%
-11.35%
20.75%
Medtronic Plc
Medtronic Plc
-1.99%
-9.34%
-13.21%
-38.74%
-23.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Align Technology Inc.
Align Technology Inc.
41.49
41.49
1.96
9.56
0.13
0.07
NA
49.94
Stryker Corporation
Stryker Corporation
38.91
38.91
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.22
63.22
1.8
2.37
0.09
0.05
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
36.4
36.4
5.19
2.76
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
33.84
33.84
5.99
4.66
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.97
28.97
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Align Technology Inc.
Align Technology Inc.
Buy
$18.4B
13.68%
41.49
11.8%
Stryker Corporation
Stryker Corporation
Buy
$129.7B
52.69%
38.91
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.3B
76.47%
63.22
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
-15.86%
36.4
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$186.6B
20.75%
33.84
13.65%
Medtronic Plc
Medtronic Plc
Buy
$102.5B
-23.49%
28.97
11.36%

Insights on Align Technology Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 956.72M → 997.43M (in $), with an average increase of 4.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 124.01M → 105.02M (in $), with an average decrease of 15.3% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 75.2%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 133.3%

Institutional Holdings

  • Vanguard Group Inc

    11.13%

  • BlackRock Inc

    10.18%

  • State Street Corporation

    4.06%

  • JPMorgan Chase & Co

    3.04%

  • AllianceBernstein L.P.

    2.37%

  • Geode Capital Management, LLC

    2.29%

Company Information

align technology is a global medical device company with industry-leading innovative products -- invisalign clear aligners and itero intraoral scanners -- that help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients. invisalign system invisalign clear aligners have been used to straighten teeth and treat minor to complex malocclusion for more than 3 million patients worldwide. the invisalign system is a combination of proprietary virtual modeling software and rapid mass-manufacturing processes used to develop a treatment plan and with custom-made aligners for each patient. invisalign is prescribed to patients through invisalign-trained orthodontists and general practitioner dentists (gp) and is offered in over 90 countries. learn more at www.invisalign.com itero intraoral scanner the itero scanner’s parallel confocal imaging technology uses optical and laser scanning to achieve a high level of precisi

Organization
Align Technology Inc.
Employees
21670
CEO
Mr. Joseph M. Hogan
Industry
Health Technology

Discover More

FAQs